The Food and Drug Administration ordered the makers of ADHD drugs to indicate the contra indications clearly to the patients, the significant ones being psychiatric and cardiovascular risks.
Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and Research said that although these drugs are immensely useful in treating patients with ADHD, the risks also should be made known to the public. He also said that FDA is working in tandem with drug manufacturers in giving information to doctors and patients on the drugs.
Some of the risks in using ADHD drugs as reported in a FDA bulletin are related to stroke, heart attacks and cardio vascular ailments. Adverse effect on the psychiatric front is also reported in a few cases.
FDA's Pediatric Advisory Committee and the Drug Safety and Risk Management Advisory Committee urged the drug companies to alter their warnings on labels in May 2006. They are also working to bring out Patient Medication Guides.